KRYSTAL-1 Trial of Adagrasib in Patients With Previously Treated Advanced KRASG12C-Mutated NSCLC: Analysis of Registrational Phase II Cohort

Source: 2022 ASCO Annual Meeting*
Download Slideset
June 3-7, 2022; Chicago, Illinois
Adagrasib monotherapy was associated with clinical activity, intracranial response, and manageable toxicity in patients with previously treated NSCLC harboring a KRASG12C mutation.
Format: Microsoft PowerPoint (.ppt)
File Size: 208 KB
Released: June 6, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings